Biosplice Announces First Patient Dosed in Phase II Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

Biosplice Therapeutics, Inc. (“Biosplice”) announced that the first patient has been dosed in a Phase II clinical trial evaluating cirtuvivint in patients with advanced soft-tissue sarcomas.